Global Health Unit, Department of Health Sciences, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
PLoS One. 2019 Jun 28;14(6):e0215577. doi: 10.1371/journal.pone.0215577. eCollection 2019.
Persistent barriers to universal access to medicines are limited social protection in the event of illness, inadequate financing for essential medicines, frequent stock-outs in the public sector, and high prices in the private sector. We argue that greater coherence between human rights law, national medicines policies, and universal health coverage schemes can address these barriers. We present a cross-national content analysis of national medicines policies from 71 countries published between 1990-2016. The World Health Organization's (WHO) 2001 guidelines for developing and implementing a national medicines policy and all 71 national medicines policies were assessed on 12 principles, linking a health systems approach to essential medicines with international human rights law for medicines affordability and financing for vulnerable groups. National medicines policies most frequently contain measures for medicines selection and efficient spending/cost-effectiveness. Four principles (legal right to health; government financing; efficient spending; and financial protection of vulnerable populations) are significantly stronger in national medicines policies published after 2004 than before. Six principles have remained weak or absent: pooling user contributions, international cooperation, and four principles for good governance. Overall, South Africa (1996), Indonesia and South Sudan (2006), Philippines (2011-2016), Malaysia (2012), Somalia (2013), Afghanistan (2014), and Uganda (2015) include the most relevant texts and can be used as models for other settings. We conclude that WHO's 2001 guidelines have guided the content and language of many subsequent national medicines policies. WHO and national policy makers can use these principles and the practical examples identified in our study to further align national medicines policies with human rights law and with Target 3.8 for universal access to essential medicines in the Sustainable Development Goals.
在发生疾病时社会保护有限、基本药物供资不足、公共部门经常出现药品短缺,以及私营部门药价高昂。我们认为,人权法、国家药物政策和全民健康覆盖计划之间更加协调一致可以解决这些障碍。我们对 1990 年至 2016 年间发布的 71 个国家的国家药物政策进行了跨国内容分析。我们根据世界卫生组织(世卫组织)2001 年制定的制定和执行国家药物政策指南以及所有 71 项国家药物政策,对将卫生系统方法与基本药物相关联的 12 项原则进行了评估,这些原则涉及国际人权法规定的负担得起药物和弱势群体供资问题。国家药物政策最常包含药物选择和高效支出/成本效益措施。四项原则(健康权、政府供资、高效支出和弱势群体的财务保护)在 2004 年后发布的国家药物政策中比之前更为有力。有六项原则仍然薄弱或缺失:统筹用户缴款、国际合作以及善治的四项原则。总体而言,南非(1996 年)、印度尼西亚和南苏丹(2006 年)、菲律宾(2011-2016 年)、马来西亚(2012 年)、索马里(2013 年)、阿富汗(2014 年)和乌干达(2015 年)包含了最相关的案文,可以作为其他环境的典范。我们的结论是,世卫组织 2001 年的指南指导了许多后来的国家药物政策的内容和措辞。世卫组织和国家政策制定者可以利用这些原则和我们研究中确定的实际案例,进一步使国家药物政策与人权法以及可持续发展目标中普及基本药物获取目标 3.8 保持一致。